share_log

BRIEF-Virpax Pharmaceuticals Inc To Develop Intranasal Cannabidiol Product To Manage Epilepsy In Adults And Children

BRIEF-Virpax Pharmaceuticals Inc To Develop Intranasal Cannabidiol Product To Manage Epilepsy In Adults And Children

简报-Virpax制药公司将开发鼻腔用大麻二醇产品来治疗成人和儿童癫痫
reuters ·  2021/09/20 09:30

Sept 20 (Reuters) - Virpax Pharmaceuticals Inc VRPX.O :

路透9月20日电-Virpax PharmPharmticals Inc VRPX.O:

* VIRPAX TO DEVELOP INTRANASAL CANNABIDIOL PRODUCT FOR THE MANAGEMENT OF EPILEPSY IN ADULTS AND CHILDREN

*VIRPAX将开发鼻内大麻二醇产品,用于治疗成人和儿童癫痫

* VIRPAX - ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS FROM NANOMERICS TO USE NANOMERIC'S MET FOR NASAL DELIVERY OF CBD FOR MANAGEMENT OF EPILEPSY IN ADULTS, CHILDREN

*VIRPAX-从NANOMERICS获得了使用NANOMERIC的MET进行CBD鼻腔给药的全球独家权利,用于治疗成人和儿童的癫痫

Source text for Eikon: ID:nBwbHlsyfa Further company coverage: VRPX.O

Eikon的源文本:ID:nBwbHlsyfa进一步的公司报道:VRPX.O

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发